Home Screener Insiders Rankings

Stock screener

0 companies Quality compoundersROIC 15%+, revenue up 8% a year for five years, net margin 15%+ 0 companies Management is buyingTwo or more insiders bought in 12 months, and bought more than they sold 0 companies Profitable growthRevenue up 20% a year for three years, free cash flow positive 0 companies Strong balance sheetDebt under half of equity, net margin 10%+

Stock: PRME × Clear all

Columns 9

Columns in the table 9 of up to 14

Clue Score

Market

Market cap Stock price % change Volume PE ratio EPS

Size

Revenue Net income Public float

Margins

Gross margin Operating margin Net margin Free cash flow margin

Returns

Return on equity Return on assets Return on invested capital

Growth

Revenue growth 1Y Revenue growth 3Y Revenue growth 5Y EPS growth 1Y EPS growth 3Y EPS growth 5Y

Balance sheet

Debt to equity R and D of revenue

Insiders

Insider net 12M Insider buyers 12M CEO holds x pay

Company

Industry Country

A measure you filter on is always shown.

Views & alerts

Save your screen. Keep the bounds you have set, and get an email when an insider trades at a company it holds. A free account does both.

Create an account Sign in

How the screen is spread

At least to At most

Stock	FY	Clue Score ↓	Market cap ↓	Stock price ↓	% change ↓	PE ratio ↓	Return on invested capital ↓	Revenue growth 3Y ↓	Net margin ↓	Insider buyers 12M ↓
PRMEPrime Medicine, Inc.	2025	48	$723.7M	$3.99	+11.45%	—	-136.18%	—	-4,342.44%	0

Showing 1–1 of 1.

Research

Stock screener
Insider trading
Rankings
How the Clue Score is made

Account

Sign in
Create an account

Legal

Disclaimer

InsiderClue shows public data for information only. Nothing on this site is investment advice or a recommendation to buy or sell a security. Scores and rankings are worked out automatically from filings and say nothing about the price. Do your own research before you invest.